Clinical Trial Update: Benralizumab in the Treatment of Patients With Severe Asthma With ABPA [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating benralizumab for severe asthma with ABPA has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Bronchopulmonary Aspergillosis
• Asthma

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: Baylor Research Institute | Conditions: ABPA, Severe Asthma | Phase 4 | Status: WITHDRAWN